Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity

Journal of Toxicology and Environmental Health - Part B: Critical Reviews

Volumn 12, Issue 5-6, 2009, Pages 473-507

  Ginsberg, Gary ^a   Neafsey, Patricia ^b   Hattis, Dale ^c   Guyton, Kathryn Z ^d   Johns, Douglas O ^d   Sonawane, Babasaheb ^d  

^a Mail Stop 11CHA ^*  (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c CLARK UNIVERSITY   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; EDETIC ACID; ENZYME INDUCING AGENT; ENZYME INHIBITOR; HOMOCYSTEINE THIOLACTONE; PARAOXON;

ALLELE; ALZHEIMER DISEASE; BRAIN CANCER; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME STRUCTURE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEALTH HAZARD; HUMAN; MONTE CARLO METHOD; NOMENCLATURE; NONHUMAN; ONTOGENY; PARKINSON DISEASE; POPULATION DISTRIBUTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CONTINENTAL POPULATION GROUPS; GENETICS, POPULATION; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MONTE CARLO METHOD; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 75749145900     PISSN: 10937404     EISSN: 15216950     Source Type: Journal    
DOI: 10.1080/10937400903158409     Document Type: Review

References (169)

1. Agkur, S. S., Ozturk, P., Sozmen, E. Y., Delen, Y., Tanyalcin, T., and Ege, B. 1999. Paroxonase and acetylcholinesterase activities in humans exposed to organophosphate compounds. J. Toxicol. Environ. Health A 58:469-474.
2. Au, W., Sierra-Torres, C., Cajas-Salazar, N., Shipp, B., and Legator, M. 1999. Cytogenic effects from exposure to mixed pesticides and the influence from genetic susceptibility. Environ. Health Perspect. 107:501-505.
3. Aubo, C., Senti, M., Marrugat, J., Tomas, M., Vila, J., Sala, J., and Masia, R. 2000. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur. Heart J. 21:33-38. (Pubitemid 30042666)
4. Augustinsson, K., and Barr, M. 1963. Age variation in plasma arylesterase activity in children. Clin. Chem. Acta 8:568-573.
5. Augustinsson, K., and Henrickson, B. 1965. Some factors regulating normal arylesterase activity of blood plasma in rats. Acta Physiol. Scand. 64:418-426.
6. Augustinsson, K., and Henrickson, B. 1969. Stress-induced alterations in arylesterase activity in the rat. Biochem. Pharmacol. 19:21-27.
7. Akhmedova, S., Yakimovsky, A., and Schwartz, E. 2001. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184:179-182.
8. Akhmedova, S., Anismov, S., Yakimovsky, A., and Schwartz, E. 1999. Gln-Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum. Hered. 49:178-179.
9. Allebrandt, K., Souza, R., and Chautard-Freire-Maia, E. 2002. Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol. Appl. Pharmacol. 180:151-156.
10. Antikainen, M., Murtomaki, S., Syvanne, M., Pahlman, R., Tahvanainen, E., Jauhiainen, M., Frick, M., and Ehnholm, C. 1996. The Gln-Arg192 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 99:883-885.
11. Atterberry, T., Burnett, W., and Chambers, J. 1997. Age-related differences in parathion and chlorpyrifos toxicity in male rats: Target and non-target esterase sensitivity and cytochrome P450-mediated metabolism. Toxicol. Appl. Pharmacol. 147:411-418.
12. Aviram, M., and Fuhrman, B. 2002. Wine flavonoids protect against LDL oxidation and atherosclerosis. Ann. NY Acad. Sci. 957:146-161.
13. Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C., and La Du, C. 1998a. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler. Thomb. Vasc. Biol. 18:1617-1624.
14. Aviram, M., Rosenblat, M., Bisgaier, C., Newton, R., Primo-Parmo, S., and La Du, B. 1998b. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1581-1590.
15. Aviram, M., Dornfeld, L., Rosenblat, M., Volkova, N., Kaplan, M., Coleman, R., Hayek, T., Presser, D., and Fuhrman, B. 2000. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: Studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 71:1062-1076.
16. Aynacioglu, A., Cascorbi, I., Mrozikiewicz, P., Nacak, M., Tapayigit, E., and Roots, I. 1999. Paraoxonase 1 mutations in a Turkish population. Toxicol. Appl. Pharmacol. 157:174-177.
17. Aynacioglu, A., and Kepekci, Y. 2000. The human paraoxonase Gln-Arg192 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int. J. Cardiol. 74:33-37.
18. Balcerzyk, A., Zak, I., and Krauze, J. 2007. Synergistic effects between Q192R polymorphism of paraoxonase 1 gene and some conventional risk factors in premature coronary artery disease. Arch. Med. Res. 38:545-550. (Pubitemid 46873816)
19. Barbieri, M., Bonafe, M., Marfella, R., Ragno, E., Giugliano, D., Franceschi, C., and Paolisso, G. 2002. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in health subjects. J. Clin. Endocrinol. Metab. 87:222-225.
20. Baum, L., Ng, H. K., Woo, K. S., Tomlinson, B., Rainer, T. H., Chen, X., Cheung, W. S., Chan, D. K., Thomas, G. N., Tong, C. S., and Wong, K. S. 2006. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin. Biochem. 39:191-195.
21. Benmoyal-Segal, L., Vander, T., Shifman, S., Bryk, B., Ebstein, R. P., Marcus, E. L., Stessman, J., Darvasi, A., Herishanu, Y., Friedman, A., and Soreq, H. 2005. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J. 19:452-454.
22. Berkowitz, G. S., Wetmur, J. G., Birman-Deych, E., Obel, J., Lapinski, R. H., Godbold, J. H., Holzman, J. R., and Wolff, M. S. 2004. In utero pesticide exposure, maternal paraoxonase activity and head circumference. Environ. Health Perspect. 112:388-391.
23. Bielicki, J., Knoff, L., Tribble, D., and Forte, T. 2001. Relative sensitivities of plasma lecithin:cholesterol acyltransferase, platelet-activating factor acetylhydrolase, and paraoxonase to in vitro gas-phase cigarette smoke exposure. Atheroslcerosis 155:71-78.
24. Blatter-Garin, M., James, R., Messmer, S., Barja, F., and Pometta, D. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: Identity of K-45 with paraoxonase. Eur. J. Biochem. 211:871-879.
25. Blatter-Garin, M., James, R., Dussoix, P., Blanche, H., Passa, P., Froguel, P., and Ruiz, J. 1997. Paraoxonase polymorphism Met-Leu55 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:62-66.
26. Brooks, A., Chadwick, C., Gelbard, H., Cory-Slechta, D., and Federoff, H. 1999. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neurone. Brain Res. 823: 1-10.
27. Broomfield, C. A., and Ford, K. W. 1991. Hydrolysis of nerve agents by plasma enzymes. ACS Conference Proceedings Series: Cholinesterases structure, function mechanism, genetics, and cell biology. Washinton DC: American Chemical Society, number 307.
28. Brophy, V., Jarvik, G., Richter, R., Rozek, L., Schellenberg, G., and Furlong, C. 2000. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 10:453-460.
29. Brophy, V., Hastings, M., Clendenning, J., Richter, R., Jarvik, G., and Furlong, C. 2001a. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77-84.
30. Brophy, V., Jampsa, R., Clendenning, J., McKinstry, L., Jarvik, G., and Furlong, C. 2001b. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68:1428-1436.
31. Bryk, B., Ben Moyal-Segal, L., Podoly, E., Livnah, O., Eisenkraft, A., Luria, S., Cohen, A., Yehezkelli, Y., Hourvitz, A., and Soreq, H. 2005. Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J. Neurochem. 92:1216-1227.
32. Butler, A., and Murray, M. 1997. Biotransformation of parathion in human liver: Participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J. Pharmacol. Exp. Ther. 280:966-973.
33. California Environmental Protection Agency. 1998. Report for the application and ambient air monitoring of chlorpyrifos (and the oxon analogue) in Tulare County during spring/summer, 1996. State of California, California Environmental Protection Agency, Air Resources Board. Project No. C96-0421 (Ambient) C96-040 (Application).
34. Carlson, C. S., Heagerty, P. J., Hatsukami, T. S., Richter, R. J., Ranchalis, J., Lewis, J., Bacus, T. J., McKinstry, L. A., Schellenberg, G. D., Rieder, M., Nickerson, D., Furlong, C. E., Chait, A., and Jarvik, G. P. 2006. TagSNP analyses of the PON gene cluster: Effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J. Lipid Res. 47:1014-1024.
35. Carpintero, A., Sanchez-Martin, M., Cabezas-Delamare, J., and Cabezas, J. 1996. Variation in serum arylesterase, beta-glucuronidase, cathepsin L and plasminogen activators during pregnancy. Clin. Chim. Acta 225:153-164.
36. Cascorbi, I., Laule, M., Mrozikiewicz, PM., Mrozikiewicz, A., Andel, C., Baumann, G., Roots, I., and Strangl, K. 1999. Mutations in the human paroxonase 1 gene: Frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 9:755-761.
37. Cellini, E., Tedde, A., Bagnoli, S., Nacmias, B., Piacentini, S., Bessi, V., Bracco, L., and Sorbi, S. 2006. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci. Lett. 408:199-202.
38. Chemnitius, J., Winkel, H., Meyer, I., Schirrmacher, K., Armstrong, V., Kreuzer, H., and Zech, R. 1998. Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease. Med. Klin. 93:135-137.
39. Chen, J., Kumar, M., Chan, W., Berkowitz, G., and Wetmur, J. G. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspect. 111:1403-1409.
40. Chen, J., Chan, W., Wallenstein, S., Berkowitz, G., and Wetmur, JG. 2005. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol. Biomarkers Prev. 14:731-734.
41. Cherry, N., Mackness, M., Durrington, P., Povey, A., Dippnall, M., Smith, T., and Mackness, B. 2002. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763-764.
42. Cole, T. B., Walter, B. J., Shih, D. M., Tward, A. D., Lusis, A. J., Timchalk, C., Richter, R. J., Costa, L. G., and Furlong, C. E. 2005. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet. Genom. 15:589-598.
43. Costa, L., and Manzo, L. 1995. Biochemical markers of neurotoxicity: Research strategies and epidemiological applications. Toxicol. Lett. 77:137-144.
44. Costa, L., Li, W., Richter, R., Shih, D., Lusis, A., and Furlong, C. 1999. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem. Biol. Interact. 119-120:429-438.
45. Costa, L. G., Cole, T. B., Vitalone, A., and Furlong, C. E. 2005a. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 352:37-47.
46. Costa, L. G., Vitalone, A., Cole, T. B., and Furlong, C. E. 2005b. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 69:541-550.
47. Cowan, J., Sinton, C., Varley, A., Wians, F., Haley, R., and Munford, R. 2001. Gene therapy to prevent organophosphate intoxication. Toxicol. Appl. Pharmacol. 173:1-6.
48. Cumming, J. 1999. Understanding Parkinson's disease. J. Am. Med. Assoc. 281:376-378.
49. Davies, H., Richter, R., Keifer, M., Broomfield, C., Sowalla, J., and Furlong, C. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:334-336.
50. Deakin, S. P., and James, R. W. 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 107:435-447.
51. Deakin, S., Leviev, I., Nicaud, V., Brulhart Meynet, M. Tiret, L., and James, R. 2002. Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J. Clin. Endocrinol. Metab. 87:1268-1273.
52. Eaton, D. L, Daroff, R. F, Autrup, H., Bridges, J., Buffler, P., Costa, L. G., Coyle, J., McKhann, G., Mobley, W. C., Nadel, L., Nubert, D., Schulte-Hermann, R., and Spencer, P. S. 2008. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit. Rev. Toxicol. 38:1-125.
53. Ecobichon, D., and Stephens, D. 1973. Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 14:41-47.
54. Erlich, P. M., Lunetta, K. L., Cupples, L. A., Huyck, M., Green, R. C., Baldwin, C. T., and Farrer, L. A. 2006. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet. 15:77-85.
55. Eskenazi, B., Harley, K., Bradman, A., Weltzien, E., Jewell, N. P., Barr, D. B., Furlong, C. E., and Holland, N. T. 2004. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ. Health Perspect. 112:1116-1124.
56. Eskenazi, B., Marks, A. R., Bradman, A., Harley, K., Barr, D. B., Johnson, C., Morga, N., and Jewell, N. P. 2007. Organophosphate pesticide exposure and neurodevelopment in young Mexican-American children. Environ. Health Perspect. 115:792-798.
57. Fanella, S., Harris, S., Young, T., Hanley, A., Zinman, B., Connelly, P., and Hegele, R. 2000. Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin. Chem. Lab. Med. 38:413-420.
58. Feingold, K., Memon, R., Moser, A., and Grunfeld, C. 1998. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307-315.
59. Fong, C. S., Cheng, C. W., and Wu, R. M. 2005. Pesticide exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurol. Taiwan 14:55-60.
60. Furlong, C. E. 2002. Comments on genetic and developmental variability of sensitivity to chlorpyrifos/chlorpyrifos oxon exposure as modulated by plasma paraoxonase (PON1). Comments provided to U.S. EPA SAP on Chlorpyrifos, http://www.epa.gov/scipoly/sap/2002/ june/chlorphyr.pdf
61. Furlong, C., Richter, R., Seidel, S., Costa, L., and Motulsky, A. 1989. Spectrophotometric assay for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/amylesterase. Anal. Biochem. 180:242-247.
62. Furlong, C., Li, W.-F., Brophy, V., Jarvik, P., Richter, R., Shih, D., Lusis, A., and Costa, L. 2000a. The PON1 gene and detoxication. Neurotoxicology 21:581-588.
63. Furlong, C., Richter, R., Shih, D., Lusis, A., Alleva, E., and Costa, L. 2000b. Genetic and temporal determinants of pesticide sensitivity: Role of paraoxonase (PON1). Neurotoxicology 21:91-100.
64. Furlong, C. E., Cole, T. B., Jarvik, G. P., Pettan-Brewer, C., Geiss, G. K., Richter, R. J., Shih, D. M., Tward, A. D., Lusis, A. J., and Costa, L. G. 2005. Role of paraoxonase (PON1) status in pesticide sensitivity: Genetic and temporal determinants. Neurotoxicology 26:651-659.
65. Furlong, C. E., Holland, N., Richter, R. J., Bradman, A., Ho, A., and Eskenazi, B. 2006. PON1 status of farm worker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genom. 16:183-190.
66. Gamboa, R., Zamora, J., Rodriguez-Perez, J. M., Fragoso, J. M., Cardoso, G., Posadas-Romero, C., and Vargas-Alarcon, G. 2006. Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exp. Mol. Pathol. 80:85-90.
67. Geldmacher-von Mallinckrodt, M., and Diepgen, T. 1988. The human serum paraoxonase-Polymorphism and specificity. Toxicol. Environ. Chem. 18:79-196.
68. Gentry, P. R., Hack, C. E., Haber, L., Maier, A., and Clewell, H. J. 2002. An approach for the quantitative consideration of geneteic polymorphism data in chemical risk assessment: Examples with warfarin and parathion. Pharmacol. Sci. 70:120-139.
69. Giles, W. H., Croft, J. B., Greenlund, K. J., Ford, E. S., and Kittner, S. J. 2000, Association between total homocysteine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Study Examination Survey. Am. Heart J. 39:446-453.
70. Ginsberg, G., Hattis, D., Sonawane, B., Russ, A., Banati, P., Kozlak, M., Smolenski, S., and Goble, R. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66:185-200.
71. Haber, L. T., Maier, A., Gentry, P. R., Clewell, H. J., and Dourson, M. L. 2002. Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Pharmacol. 35:177-197.
72. Haley, R., Billecke, S., and La Du, B. 1999. Association of low PON1 Type Q (Type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol. Appl. Pharmacol. 157:227-233.
73. Hassett, C., Richter, R., Humbert, R., Chapline, C., Crabb, J., Omiecinski, C., and Furlong, C. 1991. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 30:10141-10149.
74. He, X. M., Zhang, Z. X., Zhang, J. W., Zhou, Y. T., Tang, M. N., Wu, C. B., and Hong, Z. 2006. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin. Med. J. 119:1204-1209.
75. Hegele, R. 1999. Paraoxonase genes and disease. Ann. Med. 31:217-224.
76. Hegele, R., Connelly, P., Scherer, S., Hanley, A., Harris, S., Tsui, L., and Zinman, B. 1997. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:3373-3377.
77. Herrmann, S., Blanc, H., Poirier, O., Arveiler, D., Luc, G., Evans, A., Marques-Vidal, P., Bard, J., and Cambien, F. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 126:299-303.
78. Holland, N., Furlong, C., Bastaki, M., Richter, R., Bradman, A., Huen, K., Beckman, K., and Eskenazi, B. 2006. Paraoxonase polymorphisms, haplotypes and enzyme activity in Latino mothers and newborns. Environ. Health Perspect. 114: 985-991.
79. Hong, S., Song, J., Min, W., and Kim, J. 2001. Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin. Biochem. 34:475-481. (Pubitemid 33001317)
80. Huff, R., Corcoran, J., Anderson, J., and Abou-Donia, M. 1994. Chlorpyrifos oxon binds directly to muscarinic receptors and inhibits cAMP accumulation in rat striatum. J. Pharmacol. Exp. Ther. 269:329-335.
81. Humbert, R., Adler, D., Disteche, C., Hassett, C., Omiecinski, C., and Furlong, C. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:73-76.
82. Ikeda, T., Obayashi, H., Hasegawa G., Nakamura, N., Yoshikawa, T., Imamura, Y., Koizumi, K., and Kinoshita, S. 2001. Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am. J. Ophthalmol. 132:191-195.
83. Imai, Y., Morita, H., Kurihara, H., Sugiyama, T., Kato, N., Ebihara, A., Hamada, C., Kurihara, Y., Shindo, T., Oh-Hashi, Y., and Yazaki, Y. 2000. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435-442.
84. Inoue, M., Suehiro, T., Nakamura, T., Ikeda, Y., Kumon, Y., and Hashimoto, K. 2000. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with Type 2 diabetes Metabolism 49:1400-1405.
85. Jakubowski, H., Ambrosius, W., and Pratt, H. 2001. Genetic determinants of homocysteine thiolactonase activity in humans: Implications for atherosclerosis. FEBS Lett. 491:35-39.
86. James, R., Leviev, I., and Righetti, A. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-2257.
87. Jarvik, G., Rozek, L., Brophy, V., Hatsukami, T., Richter, R., Schellenberg, G., and Furlong, C. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease that is PON1192 or PON155 genotype. Arterioscler. Thomb. Vasc. Biol. 20:2441-2447.
88. Jokanovic, M., Kosanovic, M., and Maksimovic, M. 1996. Interaction of organophosphorus compounds with carboxylesterases in the rat. Arch. Toxicol. 70:444-450.
89. Josse, D., Lockridge, O., Xie, W., Bartels, C., Schopfer, L., and Masson, P. 2001. The active site of human paraoxonase (PON1). J. Appl. Toxicol. 21:S7-S11.
90. Kao, Y., Donaghue, K., Chan, A., Bennets, B., Knight, J., and Silink, M. 2002. Paraoxonase gene cluster is a genetic marker for early microvascular complications in Type 1 diabetes. Diabetic Med. 19:212-215.
91. Karanth, S., and Pope, C. 2000. Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. Toxicol. Sci. 58:282-289.
92. Kerkeni, M., Addad, F., Chauffert, M., Chuniaud, L., Miled, A., Trivin, F., and Maaroufi, K. 2006. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin. Biochem. 39:821-825.
93. Kleemola, P., Freese, R., Juahiainen, M., Pahlman, R., Alfthan, G., and Mutanen, M. 2002. Dietary determinants of serum paraoxonase activity in health humans. Atherosclerosis 160:425-432.
94. Kondo, I., and Yamamoto, M. 1998. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806:271-273.
95. La Du, B., Aviram, M., Billecke, S., Navab, M., Primo-Parmo, S., Sorenson, R., and Standiford, T. 1999. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 120:379-388.
96. La Du, B., Billecke, S., Hsu, C., Haley, R., and Broomfield, C. 2001. Serum paraoxonase (PON1) isozymes: The quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab. Dispos. 29:566-569.
97. Lassiter, T., Padilla, S., Mortensen, S., Chanda, S., Moser, V., and Barone, S. 1998. Gestational exposure to chlorpyrifos: Apparent protection of the fetus? Toxicol. Appl. Pharmacol. 152:56-65.
98. Le Couteur, D., McLean, A., Taylor, M., Woodham, B., and Board, P. 1999. Pesticides and Parkinson's disease. Biomed. Pharmacother. 53:122-130.
99. Leus, F., Zwart, M., Kastelein, J., and Voorbij, H. 2001. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154:641-649.
100. Leviev, I., and James, R. 2000. Promoter polymorphisms of the human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc, Biol. 20:516-521.
101. Leviev, I., Negro, F., and James, R. 1997. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17:2935-2939.
102. Leviev, I., Righetti, A., and James, R. 2001. Paraoxonase promoter polymorphism T(?107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J. Mol. Med. 79:457-463.
103. Leviev, I., Poirier, O., Nicaud, V., Evans, A., Kee, F., Arveiler, D., Morrisson, C., Cambien, F., and James, R. 2002. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 161:463-467.
104. Li, W., Furlong, C., and Costa, L. 1995. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 76:219-226.
105. Li, W., Costa, L., Richter, R., Hagen, T., Shih, D., Tward, A., Lusis, A., and Furlong, C. 2000. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767-779.
106. Li, W., Pan, M. H., Chung, M. C., Ho, C. K., and Chuang, H. Y. 2006. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ. Health Perspect. 114:1233-1236.
107. Liu, Y. J., Huang, P. L., Chang, Y. F., Chen, Y. H., Chiou, Y. H., Xu, Z. L., and Wong, R. H. 2006. GSTP1 genetic polymorphism is associated with a higher risk of DNA damage in pesticide-exposed fruit growers. Cancer Epidemiol. Biomarkers Prev. 15:659-666.
108. Mackness, B., Mackness, M., Arrol, S., Turkie, W., and Durrington, P. 1997. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122:265-268.
109. Mackness, B., Mackness, M., Arrol, S., Turkie, W., Julier, K., Abuasha, B., Miller, J., Boulton, J., and Durrington, P. 1998. Serum paraoxonase (PON1)55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349.
110. Mackness, M., Durrington, P., Ayub, A., and Mackness, B. 1999. Low serum paraoxonase: A risk factor for atherosclerotic disease? Chem. Biol. Interact. 120:389-397.
111. Mackness, B., Mackness, M., Durrington, P., Arrol, S., Evans, A., McMaster, D., Ferrieres, J., Ruidavets, J., Williams, N., and Howard, A. 2000. Paraoxonase activity in two health populations with differing rates of coronary heart disease. Eur. J. Clin. Invest. 30:4-10.
112. Mackness, M., Bouiller, A., Hennuyer, N., Mackness, B., Hall, M., Tailleux, A., Duriez, P., Delfly, B., Durrington, P., Fruchart, J., Duverger, N., Caillaud, J., and Castro, G. 2000. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem. Biophys. Res. Commun. 269:232-236.
113. Mackness, B., Davies, G., Turkie, W., Lee, E., Roberts, D., Hill, E., Roberts, C., Durrington, P., and Mackness, M. 2001. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21:1451-1457.
114. Marra, M., Marchegiani, F., Antonicelli, R., Sirolla, C., Spazzafumo, L., Olivieri, F., Franceschi, C., Testa, R., Paolisso, G., James, R. W., Boemi, M., and Parati, G. 2006. The PON1192RR genotype is associated with a higher prevalence of arterial hypertension. J. Hypertens. 24:1293-1298.
115. Mastorikou, M., Mackness, M., and Mackness, B. 2006. Defective metabolism of oxidized phospholipids by HDL from people with type 2 diabetes. Diabetes 55:3099-3103.
116. Meuller, R., Hornung, S., Furlong, C., Anderson, J., Giblett, E., and Motulsky, A. 1983. Plasma paraoxonase polymorphism: A new enzyme assay, population, family, biochemical and linkage studies. Am. J. Hum. Genet. 35:393-408.
117. Mochizuki, H., Scherer, S., Xi, T., Nickle, D., Majer, M., Huizenga, J., Tsui, L., and Prochazka, M. 1998. PON2 gene at 7q21.3: Cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149-157.
118. Mortensen, S., Chanda, S., Hooper, M., and Padilla, S. 1996. Maturational differences in chlorpyrifos-oxonase activity may contribut to age-related sensitivity to chlorpyrifos. J. Biochem. Toxicol. 11:279-287. (Pubitemid 126808227)
119. Moser, V., Chanda, S., Mortensen, S., and Padilla, S. 1998. Age and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol. Sci. 46:211-222.
120. Mueller, R., Hornung, S., Furlong, C., Anderson, J., Giblett, E., and Motulsky, A. 1983. Plasma paraoxonase polymorphism: A new enzyme assay, population, family, biochemical and linkage studies. Am. J. Hum. Genet. 35:393-408.
121. Mutch, E., Daly, A. K., and Williams, F. M. 2007. The relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver. Drug Metab. Dispos. 35:315-320.
122. Needham, L L. 2005. Assessing exposure to organophosphorus pesticides by biomonitoring in epidemiologic studies of birth outcomes. Environ. Health Perspect. 113:494-498.
123. Nishio, E., and Watanabe, Y. 1997. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiol. Biochem. Biophys. Res. Commun. 236:289-293.
124. Ng, C. J., Wadleigh, D. J., Gangopadhyay, A., Hama, S., Grijalva, V. R., Navab, M., Fogelman, A. M., and Reddy, S. T. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276:44444-44449.
125. Ng, C. J., Shih, D. M., Hama, S. Y., Villa, N., Navab, M., and Reddy, S. T. 2005. The paraoxonase gene family and atherosclerosis. Free Radical Biol. Med. 38:153-163.
126. Odawara, M., Tachi, Y., and Yamashita, K. 1997. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetic patients. J. Clin. Endocrinol. Metab. 82:2257-2260.
127. O'Leary, K. A., Edwards, R. J., Town, M. M., and Boobis, A. R. 2005 Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: Consequences for risk from exposure to diazinon. Pharmacogenet. Genom. 15:51-60.
128. Padilla, S., Buzzard, J., and Moser, V. 2000. Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and methamidophos. Neurotoxicology 21:49-56.
129. Paragh, G., Seres, I., Balogh, Z., Varga, Z., Karpati, I., Matyus, J., Ujhelyi, L., and Kakuk, G. 1998. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80:166-170.
130. Patel, B., Mackness, M., Harty, D., Arrol, S., Boot-Handford, R., and Durrington, P. 1990. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim. Biophys. Acta 1035:113-116.
131. Pinizzotto, M., Castillo, E., Fiaux, M., Temler, E., Gaillard, R., and Ruiz, J. 2001. Paraoxonase2 polymorphisms are associated with nephropathy in Type II diabetes. Diabetologia 44:104-107.
132. Pope, C. N. 1999. Organophosphate pesticides: Do they all have the same mechanisms of toxicity? J. Toxicol. Environ. Health B 2:161-181.
133. Povey, A. C., Mackness, M. I., Durrington, P. N., Dippnall, M., Smith, A. E., Mackness, B., and Cherry, N. M. 2005. Paraoxonase polymorphisms and self-reported chronic ill-health in farmers dipping sheep. Occup. Med. 55:282-286.
134. Primo-Parmo, S., Sorenson, R., Teiber, J., and La Du, B. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
135. Rao, M. N., Marmillot, P., Gong, M., Palmer, D. A., Seeff, L B., and Strader, D. B., and Laksham, M. R. 2003. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 52:1287-1294.
136. Rauh, V. A., Garfinkel, R., Perera, F P., Andrews, H. F., Hoepner, L., Barr, D. B., Whitehead, R., Tang, D., and Whyatt, R. W. 2006. Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics 118:1845-1859.
137. Richter, R., and Furlong, C. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-753.
138. Rojas-Garcia, A. E., Solis-Heredia, M. J., Pina-Guzman, B., Vega, L., Lopez-Carrillo, L., and Quintanilla-Vega, B. 2005. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol. Appl. Pharmacol. 205:282-289.
139. Roy, A., Loke, D., Saha, N., Viegas, O., Tay, J., and Ratnam, S. 1994. Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study. Gynecol. Obstet. Invest. 38:10-13.
140. Salonen, J., Malin, R., Tuornainen, T., Nyyssonen, K., Lakka, T., and Lehtimaki, T. 1999. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. Br. Med. J. 319:487-489.
141. Sanghera, D., Saha, N., Aston, C., and Kamboth, M. 1997. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1067-1073.
142. Sanghera, D., Saha, N., and Kamboh, M. 1998. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 136:217-223.
143. Schiavon, R., De Fanti, E., Giavarina, D., Biasioli, S., Cavalcanti, G., and Guidi, G. 1996. Serum paraoxonase activity is decreased in uremic patients. Clin. Chim. Acta 247:71-80.
144. Selhub, J. 1999. Homocysteine metabolism. Annu. Rev. Nutr. 19:217-246.
145. Searles Nielsen, S., Mueller, B. A., DeRoos, A. J., Viernes, H. M., Farin, F. M., and Checkoway, H. 2005. Risk of brain tumors in children and susceptibility to organophosphorus insecticides: The potential role of paraoxonase (PON1). Environ. Health Perspect. 113:909-913.
146. Sen-Banerjee, S., Siles, X., and Campos, H. 2000. Tobacco smoking
147. Senti, M., Tomas, M., Anglada, R., Elosua, R., Marrugat, J., Covas, M. I.,and Fito, M. 2003. Inter-relationship of smoking, paraoxonase activity, and leisure time physical activity: A population-based study. Eur. J. Int. Med. 14:78-184.
148. Serrato, M., and Marian, A. 1995. A variant of human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:3005-3008.
149. Sirivarasai, J., Kaojarern, S., Yoovathaworn, K., and Sura, T. 2007. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects. Chem. Biol. Interact. 168:184-192.
150. Shih, D., Gu, L., and Xia, Y. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287.
151. Shih, D., Xia, Y., Wang, X., Miller, E., Castellani, L., Subbanagounder, G., Cheroutre, H., Faull, K., Berliner, J., Witztum, J., and Lusis, A. 2000. Combined serum paraoxonase knockout/alipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275:17527-17535.
152. Smolen, A., Eckerson, H., Gan, K., Hailat, N., and La Du, B. 1991. Characteristics of the genetically determined polymorphic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19:107-112.
153. Sorenson, R., Bisgaier, C., Aviram, M., Billecke, S., and La Du, B. 1999. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with high density lipoproteins by binding phospholipids: Apolipoprotein A-1 stabilizes activity. Atheroscler. Thromb. Vasc. Biol. 19:2214-2225.
154. Suehiro, T., Nakatichi, Y., Yamarnoto, M., Arii, K., Itoh, H., Hamashige, N., and Hashimoto, K. 1996. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 15:69-73.
155. Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumon, Y., Shindo, M., Tanaka, H., and Hashimoto, K. 2000. A polymorphism up-stream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295-298.
156. Sutherland, W., Walker, R., De Jong, S., Van Rij, A., Phillips, V., and Walker, H. 1999. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler. Thromb. Vasc. Biol. 19:1340-1347.
157. Taylor, M., Couteur, D., Mellick, G., and Board, P. 2000. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J. Neural Transmission 107:979-983.
158. Tripi, L. M., Manzi, S., Chen, Q., Kenney, M., Shaw, P., Kao, A., Bontempo, F., Kammerer, C., and Kamboh, M. I. 2006. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum. 54:1928-1939.
159. Turban, S., Fuentes, F., Ferlic, L., Brugada, R., Gotto, A.M., Ballantyne, C. M., and Marian, A. J. 2001. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression, and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atheroschlerosis 154:633-640.
160. Vitarius, J., and Sultatos, L. 1994. Kinetic mechanism of the detoxification of the organophosphate paraoxon by human serum Aesterase. Drug Metab. Dispos. 22:472-478. (Pubitemid 24158549)
161. Vitarius, J., and Sultatos, L. 1995. The role of calcium in the hydrolysis of the organophosphate paraoxon by human serum A-esterase. Life Sci. 56:125-134.
162. Voetsch, B., Benke, K., Damasceno, B., Siqueira, L., and Loscalzo, J. 2002. Paraoxonase 192 Gln ?Arg polymorphism. An independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33:1459-1464.
163. Weitman, S., Vodicnik, M., and Lech, J. 1983. Influence of pregnancy on parathion toxicity and disposition. Toxicol. Appl. Pharmacol. 71:215-224.
164. Whyatt, R. M., Camann, D., Perera, F. P., Rauh, V. A., Tang, D., Kinney, P. L., Garfinkel, R., Andrews, H., Hoepner, L., and Barr, D. B. 2005. Biomarkers in assessing residential insecticide exposures during pregnancy and effects on fetal growth. Toxicol. Appl. Pharmacol. 206:246-254.
165. Wolff, M. S., Engel, S., Berkowitz, G., Teitelbaum, S., Siskind, J., Barr, D. B., and Wetmur, J. 2007. Prenatal pesticide and PCB exposures and birth outcomes. Pediatr. Res. 61:243-250.
166. Yuknavage, K., Fenske, R., Kalman, D., Keifer, M., and Furlong, C. 1997. The effect of organophosphate pesticide dermal contamination on field cholinesterase biomonitoring, results of capillary samples. J. Toxicol. Environ. Health 51:35-55.
167. Zama, T., Murata, M., Matsubara, Y., Kawano, K., Aoki, N., Yoshino, H., Watanbe, G., Ishikawa, K., and Ikeda, Y. 1997. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:3565-3569.
168. Zech, R., and Zurcher, K. 1974. Organophosphate splitting enzymes in different mammals. Comp. Biochem. Physiol. 48B:427-433.
169. Zintzaras, E., and Hadjigeorgiou, G. M. 2004. Association of paraoxon 1 gene polymorphisms with risk of Parkinson's disease: A metaanalysis. J. Hum. Genet. 49:474-481.